These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36870876)

  • 1. COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Ludwikowska KM; Popiel A; Matkowska-Kocjan A; Olbromski MJ; Biela M; Wójcik M; Szenborn F; Wielgos K; Pielka-Markiewicz E; Zaryczański J; Kursa MB; Szenborn L
    Vaccine; 2023 Mar; 41(13):2289-2299. PubMed ID: 36870876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Ludwikowska KM; Popiel A; Matkowska-Kocjan A; Biela M; Wójcik M; Szenborn F; Wielgos K; Pielka-Markiewicz E; Zaryczański J; Kursa MB; Szenborn L
    Vaccine; 2023 May; 41(21):3317-3327. PubMed ID: 37087396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Results from an active pharmacovigilance study in central Italy.
    Ripabelli G; Sammarco ML; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Romano R; Licianci A; Tamburro M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2126668. PubMed ID: 36315849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Thomas SJ; Perez JL; Lockhart SP; Hariharan S; Kitchin N; Bailey R; Liau K; Lagkadinou E; Türeci Ö; Şahin U; Xu X; Koury K; Dychter SS; Lu C; Gentile TC; Gruber WC
    Vaccine; 2022 Mar; 40(10):1483-1492. PubMed ID: 35131133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study.
    Paschou SA; Karalis V; Psaltopoulou T; Vasileiou V; Charitaki I; Bagratuni T; Ktena V; Papandroulaki F; Gumeni S; Kassi GN; Trougakos IP; Terpos E; Dimopoulos MA
    Front Endocrinol (Lausanne); 2022; 13():840668. PubMed ID: 35273575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis.
    Matson RP; Niesen MJM; Levy ER; Opp DN; Lenehan PJ; Donadio G; O'Horo JC; Venkatakrishnan AJ; Badley AD; Soundararajan V
    Lancet Digit Health; 2023 Apr; 5(4):e206-e216. PubMed ID: 36963910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project.
    Polewska K; Tylicki P; Biedunkiewicz B; Rucińska A; Szydłowska A; Kubanek A; Rosenberg I; Rodak S; Ślizień W; Renke M; Dębska-Ślizień A; Tylicki L
    Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357013
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
    Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
    Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
    Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
    Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss.
    Yanir Y; Doweck I; Shibli R; Najjar-Debbiny R; Saliba W
    JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):299-306. PubMed ID: 35201275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study.
    Rogers A; Rooke E; Morant S; Guthrie G; Doney A; Duncan A; Mackenzie I; Barr R; Pigazzani F; Zutis K; MacDonald TM
    BMJ Open; 2022 Jun; 12(6):e060583. PubMed ID: 35649591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
    Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM
    JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
    Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
    Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
    J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.